... with comparable results and better tolerability than chemotherapy. We conducted this study to see if mutations in the epidermal growth factor receptor (EGFR) might predict the therapeutic benefit in HNSCC patients. Patients and Methods: In a pilot trial, 8 patients with metastatic or recurrent HNSCC were treated...

... and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK...

.... The role of the epidermal growth factor receptor (EGFR) and other molecules linked to the EGFR signaling pathway has been extensively studied, and they have become the target of new, specific therapies in lung adenocarcinomas. Similarly, the amplification of the fibroblast growth factor receptor 1 (FGFR1...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. EGFR Mutation Gefitinib...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Non-small cell lung cancer NSCLC Survival Epidermal growth factor receptor EGFR Gefitinib Second primary tumour...

... on the biologic background and latest developments in the treatment of this particular entity. Never-smoker NSCLC EGFR EML4-ALK Targeted therapy Review Article · Übersichtsarbeit Onkologie 2011;34:202 207 DOI: 10.1159/000326839 Published online: March 18, 2011 Non-Small Cell Lung Cancer in Never...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Trastuzumab EGFR HER-2 Gastric cancer Case Report · Kasuistik Onkologie 2011;34:42 45 DOI: 10.1159/000323345 Published online: January 17, 2011 Trastuzumab plus...

... feasibility of front-line administration of gefitinib for the treatment of non-small cell lung carcinomas (NSCLCs) harboring intragenic epidermal growth factor receptor (EGFR) mutations. The experience of the use of this EGFR tyrosine kinase inhibitor (TKI) in non-Asian subjects remains limited. Patients...

...Jessica C. Hassel; Melanie Kripp; Salah Al-Batran; Ralf-Dieter Hofheinz Background: Skin toxicities are frequent in patients receiving epidermal growth factor receptor (EGFR) antagonists. Grading and management of these skin reactions are poorly standardized. Materials and Methods: We conducted...

... (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib. Case Reports: We present the follow-up data of 2 EGFR mutation-positive stage IV NSCLC patients who received upfront 250 mg gefitinib daily, then underwent potentially curative surgery, and resumed gefitinib therapy in the adjuvant...

...Zhen Wang; Yi Long Wu; Guo Chun Zhang; Qing Zhou; Chong Rui Xu; Ai Lin Guo Background: For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. It is known...